Zydus Lifesciences Limited
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the…
What Zydus files
- Updates160
- Others92
- Investor Meet40
- Important35
- PPTs12
- Dividend/Bonus11
CRISIL Ratings has reaffirmed Zydus Lifesciences' credit ratings across its bank facilities (Rs. 4,724 Cr), Commercial Papers (Rs. 200 Cr), and Non-Convertible Debentures (Rs. 125 Cr). The long-term rating stands at CRISIL AAA with a Stable outlook, while the short-term rating is CRISIL A1+. This top-tier rating reflects the company's...
Zydus Lifesciences Limited will participate in the J.P. Morgan India Conference to engage with institutional investors and discuss ongoing business developments and strategic growth initiatives.
Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Zydus Lifesciences' subsidiary in the US has agreed to a settlement of USD 5.9 million to resolve past litigation matters.
Zydus Lifesciences' FY26 revenues rose 17% to Rs. 27,150 Cr with 31.2% EBITDA. US FDA granted Saroglitazar NDA Priority Review, targeting Q4 FY27 launch. The company declared Re. 1 dividend and approved a Rs. 1,100 Cr share buyback, forecasting high-teen revenue growth for FY27.